Actively Recruiting
Study of Zavegepant Nasal Spray to Evaluate Safety and How It Is Processed in Children With Migraine History
Led by Pfizer · Updated on 2026-09-28
16
Participants Needed
14
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety and how the body processes the medicine Zavegepant PF-07930207 in children aged 6 to less than 12 years who have a history of migraine for at least 6 months. The study focuses on understanding how the medicine is absorbed, changed, and removed from the body after administration. All participants will receive a single dose of Zavegepant as a nasal spray, with the dose depending on their weight. The spray is given once into one nostril. The study will observe the participants experiences, including possible benefits and unwanted effects, during the treatment period. Participants will be involved in the study for up to 10 weeks, which includes 3 visits to the study clinic and 2 follow-up phone calls. Researchers will collect blood samples to measure the medicines levels in the body at specified times and will monitor safety through vital signs, laboratory tests, and questionnaires on mood and behavior.
CONDITIONS
Brief Title
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here